Literature DB >> 14581411

Epiregulin as a major autocrine/paracrine factor released from ERK- and p38MAPK-activated vascular smooth muscle cells.

Masanori Takahashi1, Ken'ichiro Hayashi, Kenji Yoshida, Yasuyuki Ohkawa, Toshi Komurasaki, Akira Kitabatake, Akira Ogawa, Wataru Nishida, Masahiko Yano, Morito Monden, Kenji Sobue.   

Abstract

BACKGROUND: The coordinated activation of extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein kinase (p38MAPK) is critical for the induction of vascular and visceral smooth muscle cell (SMC) dedifferentiation. We previously reported that on the forced activation of both MAPKs, visceral SMCs secrete a non-heparin-binding protein factor(s) that is involved in the dedifferentiation of neighboring SMCs. In this study, we sought to identify the dedifferentiation factor(s) derived from vascular SMCs (VSMCs). METHODS AND
RESULTS: We fractionated the VSMC dedifferentiation factor(s) in the conditioned medium obtained from differentiated VSMCs in which both ERK and p38MAPK were forcedly activated and identified epiregulin as a major autocrine/paracrine factor for VSMC dedifferentiation. The epiregulin-induced VSMC dedifferentiation was mediated through the coordinated activation of ERK and p38MAPK. Unsaturated lysophosphatidic acid and platelet-derived growth factor-BB, which are potent VSMC dedifferentiation factors, rapidly upregulated epiregulin mRNA expression in an ERK- and p38MAPK-dependent manner. Reverse transcriptase-polymerase chain reaction and/or immunohistological analyses revealed the restricted expression of epiregulin in human atherosclerotic and balloon-injured rat arteries, in which the phenotypic modulation of medial VSMCs occurred in vivo.
CONCLUSIONS: Epiregulin is released from VSMCs primed by atherogenic factors and acts as a major autocrine/paracrine factor for VSMC dedifferentiation. It may be involved in the progression of vascular remodeling such as atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14581411     DOI: 10.1161/01.CIR.0000096482.02567.8C

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  32 in total

1.  Differences in genetic signaling, and not mechanical properties of the wall, are linked to ascending aortic aneurysms in fibulin-4 knockout mice.

Authors:  Jungsil Kim; Jesse D Procknow; Hiromi Yanagisawa; Jessica E Wagenseil
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-05-01       Impact factor: 4.733

2.  Sildenafil promotes smooth muscle preservation and ameliorates fibrosis through modulation of extracellular matrix and tissue growth factor gene expression after bilateral cavernosal nerve resection in the rat.

Authors:  Fara Sirad; Su Hlaing; Istvan Kovanecz; Jorge N Artaza; Leah A Garcia; Jacob Rajfer; Monica G Ferrini
Journal:  J Sex Med       Date:  2011-01-26       Impact factor: 3.802

Review 3.  Epiregulin: roles in normal physiology and cancer.

Authors:  David J Riese; Richard L Cullum
Journal:  Semin Cell Dev Biol       Date:  2014-03-12       Impact factor: 7.727

4.  A disintegrin and metalloprotease 17 mediates neointimal hyperplasia in vasculature.

Authors:  Akira Takaguri; Keita Kimura; Akinari Hinoki; Allison M Bourne; Michael V Autieri; Satoru Eguchi
Journal:  Hypertension       Date:  2011-02-28       Impact factor: 10.190

Review 5.  Diversification of caldesmon-linked actin cytoskeleton in cell motility.

Authors:  Taira Mayanagi; Kenji Sobue
Journal:  Cell Adh Migr       Date:  2011-03-01       Impact factor: 3.405

6.  Increased epidermal growth factor-like ligands are associated with elevated vascular nicotinamide adenine dinucleotide phosphate oxidase in a primate model of atherosclerosis.

Authors:  Bojana Stanic; Deepesh Pandey; David J Fulton; Francis J Miller
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-08-09       Impact factor: 8.311

7.  Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas.

Authors:  Shaowei Li; Fumiko Takeuchi; Ji-An Wang; Qingyuan Fan; Toshi Komurasaki; Eric M Billings; Gustavo Pacheco-Rodriguez; Joel Moss; Thomas N Darling
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-21       Impact factor: 11.205

8.  Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.

Authors:  N Sunaga; K Kaira; H Imai; K Shimizu; T Nakano; D S Shames; L Girard; J Soh; M Sato; Y Iwasaki; T Ishizuka; A F Gazdar; J D Minna; M Mori
Journal:  Oncogene       Date:  2012-09-10       Impact factor: 9.867

9.  MicroRNA-145 regulates platelet-derived growth factor-induced human aortic vascular smooth muscle cell proliferation and migration by targeting CD40.

Authors:  Yumei Li; Jiangnan Huang; Zhiyuan Jiang; Yuanli Zhong; Mingjie Xia; Hui Wang; Yang Jiao
Journal:  Am J Transl Res       Date:  2016-04-15       Impact factor: 4.060

10.  Fractalkine has anti-apoptotic and proliferative effects on human vascular smooth muscle cells via epidermal growth factor receptor signalling.

Authors:  Gemma E White; Thomas C C Tan; Alison E John; Carl Whatling; William L McPheat; David R Greaves
Journal:  Cardiovasc Res       Date:  2009-10-19       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.